EXACT Sciences Co. (NASDAQ:EXAS) – Stock analysts at Jefferies Financial Group boosted their FY2021 earnings per share estimates for shares of EXACT Sciences in a research note issued to investors on Thursday, January 9th, according to Zacks Investment Research. Jefferies Financial Group analyst B. Couillard now expects that the medical research company will post earnings per share of $0.69 for the year, up from their prior forecast of $0.68. Jefferies Financial Group currently has a “Buy” rating and a $120.00 target price on the stock.
Other equities analysts have also issued research reports about the stock. Benchmark upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a report on Monday, September 23rd. BTIG Research started coverage on shares of EXACT Sciences in a report on Friday, January 10th. They issued a “buy” rating and a $127.00 target price on the stock. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Friday, January 10th. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Thursday, October 17th. Finally, Oppenheimer started coverage on shares of EXACT Sciences in a report on Thursday, September 26th. They issued an “outperform” rating and a $130.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $122.06.
Shares of NASDAQ:EXAS opened at $88.06 on Monday. The company has a current ratio of 2.75, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. EXACT Sciences has a 52 week low of $75.35 and a 52 week high of $123.99. The firm’s fifty day moving average is $92.24 and its 200-day moving average is $100.38.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, October 29th. The medical research company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.10. The company had revenue of $218.81 million for the quarter, compared to analyst estimates of $216.14 million. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. EXACT Sciences’s revenue was up 85.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.37) earnings per share.
In other news, insider G Bradley Cole sold 10,000 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $90.30, for a total transaction of $903,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.20% of the company’s stock.
Large investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new stake in shares of EXACT Sciences during the second quarter worth about $35,000. Harvest Fund Management Co. Ltd bought a new stake in EXACT Sciences in the 2nd quarter worth about $43,000. Steward Partners Investment Advisory LLC grew its position in EXACT Sciences by 129.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 497 shares of the medical research company’s stock worth $45,000 after purchasing an additional 280 shares in the last quarter. HM Payson & Co. bought a new stake in EXACT Sciences in the 2nd quarter worth about $59,000. Finally, Shine Investment Advisory Services Inc. grew its position in EXACT Sciences by 31.8% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock worth $47,000 after purchasing an additional 125 shares in the last quarter. 86.66% of the stock is owned by institutional investors.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.